4
Changes in Ownership
Karyopharm Therapeutics Inc. Filed Acc 0001209191-20-037229
Chief Executive Officer sold 7,500 shares at an average $16.37 ($122,779)
- Chief Executive Officer acquired 7,500 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kauffman Michael · Chief Executive Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-06-15 | Exercise or conversion : show line 1 in the form | +7,143 | $0.03 | $236 | 763,632 | I |
| 2020-06-15 | Sale : show line 2 in the form | −7,143 | $16.38 | $116,996 | 756,489 | I |
| 2020-06-15 | Exercise or conversion : show line 3 in the form | +357 | $0.03 | $12 | 756,846 | I |
| 2020-06-15 | Sale : show line 4 in the form | −357 | $16.20 | $5,783 | 756,489 | I |
| Open-market sales · 7,500 sh · avg $16.37 · $122,779 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2020-06-15 | Exercise or conversion : show line 5 in the form Stock Option (right to buy) | −7,143 | $0.03 | 2020-10-31 | 7,143 | 16,424 | I |
| 2020-06-15 | Exercise or conversion : show line 6 in the form Stock Option (right to buy) | −357 | $0.03 | 2020-10-21 | 357 | 0 | I |
Loading xslF345X03/doc4.xml…